Alogliptin After Acute Coronary Syndrome in Patients With Type 2 Diabetes

Study Questions:

What are the cardiovascular outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo in patients with type 2 diabetes (DM2) who had a recent acute coronary syndrome?